Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9002306 | Biochemical Pharmacology | 2005 | 9 Pages |
Abstract
Elevated serum tumor necrosis factor alpha (TNF-α) levels predict mortality in patients with alcoholic liver disease. Administration of anti-TNF-α antibodies, obliteration of Kupffer cells or gut sterilization protect against ethanol-induced hepatocellular injury in animal models. In this study, we evaluated the in vivo efficacy of an antisense phosphorothioate oligodeoxynucleotide (S-ODN) targeted against TNF-α mRNA (TJU-2755). Naïve rats that were administered TJU-2755 (10 mg/(kg body weight (BW)/day) for 2 days) in the free form were challenged with LPS to induce TNF-α secretion. Antisense TJU-2755 treatment reduced serum TNF-α levels by 62%. A comparison of the efficacies of mismatched and random S-ODNs with that of TJU-2755 showed that some non-specific inhibition might accompany the sequence-specific effects of TJU-2755. To optimize the targeting of the S-ODN, TJU-2755 was encapsulated in pH-sensitive liposomes for in vivo delivery to macrophages. The efficacy of liposome-encapsulated TJU-2755 was assessed in ethanol-fed animals that were administered LPS to induce liver injury. Liposomal delivery of TJU-2755 allowed a much lower dose (1.9 mg/kg BW/day, for 2 days) of the S-ODN to reduce LPS-induced serum TNF-α (by 54%) and liver injury (by 60%) in ethanol-fed rats. These data indicate that liposome-encapsulated S-ODNs targeted against TNF-α have therapeutic potential in the treatment of alcoholic liver disease.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Biddanda C. Ponnappa, Yedy Israel, Maria Aini, Feng Zhou, Rachel Russ, Qing-na Cao, Yiyang Hu, Raphael Rubin,